World How France missed out on a Nantes start-up which manufactures a vaccine
59% of Americans Say Vaccine Rollout Happening Too Slowly in Their State: Poll
The Biden administration is "inheriting a huge mess" on the rollout of vaccines, said incoming White House Chief of Staff Ron Klain on Sunday.The COVID-19 vaccines from Pfizer and Moderna were both approved for emergency use authorization by the U.S. Food and Drug Administration last month. But as of Saturday, only about 10.6 million Americans have received a vaccine, according to the Centers for Disease Control and Prevention. As of Sunday, there are 23 million reported COVID-19 cases in the U.S., according to data from Johns Hopkins University, and the nation is nearing 400,000 deaths.
With the announcement ofagainst the , we could think that France was out of the race in the vaccination file. And yet, among the more than 200 companies around the world that jumped into a vaccine race last spring, there is Valneva. This small French start-up based in Nantes will market its own remedy in the fall. But the first doses of this tricolor company will go directly ... to the United Kingdom.
Why Israel’s Vaccine Success Might Be Hard to Replicate
A credible health-care system may be the key determinant to success.It’s the kind of standout success one would expect from the now-familiar stars of the global response to COVID-19—Taiwan, South Korea, or New Zealand. But it’s actually been achieved by Israel, in several respects a surprising country to be the world’s front-runner on vaccine distribution. A 2019 Johns Hopkins study ranked Israel an unspectacular 54th among 195 countries in terms of preparedness for a pandemic. After initially appearing to vanquish the coronavirus, Israel has since suffered some of the world’s worst outbreaks—something that remains true as it celebrates its vaccine advances.
>> LIVE -A vaccine which uses a particular technique
And this makes perfect sense when we know that it is the British who have fully funded the clinical trials of this vaccine which uses a very specific technique. "You take a virus, you inactivate it and you keep its surface intact to generate a large number of antibodies and as varied as possible", explains at the microphone of Europe 1 Franck Grimaud, CEO of Valneva. An adjuvant is then added to the vaccine to "improve the efficacy and especially the duration of protection".
California Hospitals Blame Poor Vaccine Rollout on Lack of Transparency From Government
Hospital officials in California argue vaccine rollouts across the nation were politicized by the former administration, but they are unsure if the Biden administration will be able to supply the vaccine the state desperately needs.But the delay has nothing to do with the state's health care systems, hospital officials told Newsweek. The issue stems from a lack of transparency from the federal government.
60 million doses early 2022
A vaccine that is much easier to store than that of the American-German tandem Pfizer-BioNTech, which must remain at -80 degrees Celsius, and which can be adapted to new variants in just a few months . If it is still necessary to wait several months and the end of clinical trials to validate the efficacy of this candidate vaccine, the European Union has nevertheless shown great interest. A contract will soon be signed between the 27 and the start-up to deliver 60 million doses at the start of 2022, after the vaccine has been approved by the European Medicines Agency.
COVID-19 Vaccine Developers Ask the SEC to Help Keep the Secret of How They Set Prices .
Pfizer, Johnson & Johnson and other drug companies are working to block votes on shareholder resolutions that would force the companies to disclose how government funding affects their drug pricing.Now, two of the companies awarded those contracts—Pfizer and Johnson & Johnson—are trying to prevent shareholders from voting on resolutions to require the companies to disclose information about the impact of government funding on vaccine access.